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nign	prostatic	hypertrophy	 (BPH,	eg,	 tamsulosin).	 Some	antidepressants	and	antipsy-
chotics have been reported to have α1	affinity.	This	study	examined	101	clinical	drugs	
and laboratory compounds to build a comprehensive understanding of α1-adrenoceptor	
subtype	affinity	and	selectivity.	[3H]prazosin	whole-cell	binding	was	conducted	in	CHO	









had very similar α1A/α1B/α1D-adrenoceptor	pharmacological	profiles.	Selective	sero-
tonin	 reuptake	 inhibitors	 (antidepressants)	had	poor	α1-adrenoceptor	affinity.	Several	
tricyclic	antidepressants	(eg,	amitriptyline)	and	antipsychotics	(eg,	chlorpromazine	and	
risperidone)	had	high	α1-adrenoceptor	affinities,	 similar	 to,	or	higher	 than,	α blockers 
prescribed	for	hypertension	and	BPH,	whereas	others	had	poor	α1	affinity	(eg,	protrip-
tyline,	sulpiride,	amisulpiride,	and	olanzapine).	The	addition	of	α blockers for the man-
agement	of	hypertension	or	BPH	in	people	already	taking	tricyclic	antidepressants	and	
certain	antipsychotics	may	not	be	beneficial.	Awareness	of	the	α-blocking	potential	of	
different antipsychotics may affect the choice of drug for those with delirium where ad-
ditional	hypotension	(eg,	in	sepsis)	may	be	detrimental.
K E Y W O R D S
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1  | INTRODUC TION
The α1-adrenoceptors	 are	 expressed	 in	 a	 wide	 range	 of	 tissues	
including	blood	vessels,	kidney,	spleen,	liver,	brain,	and	lower	uri-
nary tract.1-3 There are three subtypes: α1A,	α1B,	and	α1D-adre-
noceptors.1-4	All	are	present	in	blood	vessels,	and	whilst	α1A	and	
α1D	 and	 are	 both	 important	 in	 smooth	muscle	 contraction	 (and	
control	 of	 blood	pressure),	 the	 role	 of	 the	α1B-adrenoceptors	 is	
less certain.2,3,5,6







agement of resistant hypertension.
α blockers are also used in benign prostatic hypertrophy 
(BPH)	 where	 α1A	 blockade	 induces	 prostate	 and	 lower	 uri-
nary	 tract	 smooth	muscle	 relaxation,	 improving	urinary	 flow.9 
Phenoxybenzamine	was	the	first	α	blocker	to	be	used	in	BPH10 
although its α2 effects limited its use.11 The nonselective 
α1-antagonists	 doxazosin,	 terazosin,	 indoramin,	 and	 prazosin	
were	 used	 effectively	 for	 BPH,	 but	 caused	 hypotension,	 par-
ticularly	 postural	 hypotension,	 and	 required	 dose	 titration	 to	
manage this problematic side effect.9,12 Selective α1A-antag-
onists	 were	 developed,	 hoping	 to	 minimize	 hypotension	 by	
reducing α1B-antagonsim.11,13	 Tamsulosin,	 alfuzosin,	 and	 si-
lodosin	 were	 developed	 as	 prostate-specific	 (α1A	 selective)	
drugs and are used without dose titration.9 Despite reports of 
“better	 tolerability,”11,14	 alfuzosin	 is	 reported	 to	 be	 a	 nonse-
lective α1-antagonist	 and	 tamsulosin	 to	 have	 equal	 α1A-	 and	
α1D-adrenoceptor	 affinity,15,16 suggesting they may be phar-
macologically indistinguishable from drugs used for hyper-
tension.	 Indeed,	 tamsulosin	 (the	 most	 commonly	 prescribed	
α	 blocker	 for	 BPH)	 is	 associated	 with	 increased	 hypotension,	
falls,	and	fractures.12,13,17	Although	effective	for	BPH,	silodosin	
appears	 to	have	more	 sexual	 side	effects,	whereas	 its	 cardio-
vascular effects remain uncertain.18
α1-adrenoceptors	are	the	most	abundant	adrenoceptors	in	the	
brain and modulate neurotransmitter release.3 Many antidepres-
sants	 prevent	 the	 reuptake	 of	 neurotransmitters	 (serotonin	 and	
noradrenaline),	and	therefore	increase	synaptic	neurotransmitter	
concentration.	However,	several	antidepressants	have	significant	
α1-adrenoceptor	affinity.19-21 This high affinity is seen in brain ho-
mogenates.22	 In	theory	these	two	effects	 (increased	neurotrans-
mitter	presence,	but	 receptor	blockade)	 could	cancel	each	other	
out.20	However,	 antidepressants	 cause	 hypotension,	 particularly	








postural hypotension seen with several antipsychotics correlates 
well with the α1A-adrenoceptor	affinity.29	Antipsychotic	drug	use	
is also associated with falls and hip fractures and regular use is 
associated	with	 twice	 the	 risk	of	 falls	 (even	 after	 controlling	 for	
other risks31,32).
There	are	many	studies	examining	the	affinity	of	α1-adrenocep-
tor ligands. Many are older studies before the identification of the 
three subtypes and many are in whole tissue where multiple sub-
types will be present. Most studies only report the two or three li-
gands	under	investigation.	Here	we	aimed	to	investigate	the	subtype	









supplier	 code	 from	 which	 it	 was	 purchased,	 is	 given	 in	 Table	 S1.	
White-sided	view	plates	were	from	Greiner	Bio-one,	Kremsmunster,	
Austria;	and	[3H]prazosin,	Microscint	20,	and	scintillation	fluid	from	
PerkinElmer	 (Buckinghamshire,	 UK).	 Fetal	 calf	 serum	 was	 from	





of the human α1A-adrenoceptor,	human	α1B-adrenoceptor	 (DNAs	
from	Guthrie	DNA	Resource	Centre),	or	human	α1D-adrenoceptor	
(full-length	 DNA	 from	 Andre	 Pupo33;	 using	 Lipofectaime	 and	
Optimem	according	to	the	manufacturers’	instructions.	Transfected	





CHO	 cells	 were	 grown	 in	 Dulbecco's	 modified	 Eagle's	 medium	
nutrient	 mix	 F12	 (DMEM/F12)	 containing	 10%	 fetal	 calf	 serum	
and	 2	mmol/L	 L-glutamine	 in	 a	 37°C	 humidified	 5%	CO2:	 95%	 air	
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atmosphere.	Cells	were	seeded	into	white-sided,	clear	bottomed	96-
well view plates and grown to confluence.
2.4 | [3H]prazosin binding—saturation binding
The	KD	value	 for	 [3H]prazosin	was	determined	 in	each	cell	 line	by	
saturation	 binding.	 [3H]prazosin	was	 diluted	 in	 serum-free	media.	
Media	were	removed	from	each	well	and	replaced	with	either	100	µL	




for	 2	 hour	 at	 37°C	 in	 a	 humidified	 5%	CO2:	 95%	 air	 atmosphere.	
After	2	hours,	the	cells	were	washed	twice	by	the	addition	and	re-
moval	of	2	×	200	µL	cold	(4°C)	phosphate-buffered	saline.	100	µL	
Microscint 20 was added to each well and a white base applied to the 
plate	 to	 convert	 the	wells	 into	white-sided/white-bottomed	wells.	
Plates	were	 left	 at	 room	 temperature	 for	 at	 least	 6	 hours	 before	
being	counted	on	a	Topcount	(PerkinElmer),	with	a	counting	time	of	
2 minutes per well.
2.5 | [3H]prazosin whole-cell binding—
competition binding







were washed as above. Cells were inspected under a light micro-
scope to ensure cells were still present after the wash and before 
the	addition	of	Microscint	20.	In	a	few	cases,	high	concentrations	




and α1B)	 or	 100	µmol/L	 tamsulosin	 (α1D)	was	 defined	 in	 every	
plate.
Sodium	 thiosulfate	 reacts	 with	 2-chloroethylamines	 in	 a	 1:1	





When	 used,	 competing	 ligands	were	 serially	 diluted	 in	 serum-free	
media	(just	as	above)	in	the	absence	and	presence	of	thiosulfate	and	
both	dilution	series	were	then	incubated	for	30	minutes	at	37°C	(5%	
CO2,	 humidified	 atmosphere).	 Media	 was	 then	 removed	 from	 the	
cells	and	competing	ligand	(in	the	presence	or	absence	of	thiosulfate)	
added	to	the	wells	immediately	followed	by	[3H]prazosin	(thus	thio-
sulfate was present with the competing ligand for 30 minutes before 
addition	to	the	cells,	and	then	throughout	the	2-hour	incubation	with	
cells	at	1	mmol/L).
[3H]prazosin	 concentrations	were	 determined	 from	 taking	 the	





membrane-binding	 studies,	 physiological	 levels	 of	 intracellular	 en-
dogenous	GTP	will	therefore	always	have	been	present.	Although	it	
should	not	make	much	difference	for	antagonists,	the	receptors	(and	
therefore	measurements	 taken)	 in	 this	 living	 system	are	 therefore	






The	 following	 equation	 was	 then	 fitted	 to	 the	 data	 using	
Graphpad	Prism	7	and	the	IC50 was then determined as the concen-
tration	required	to	inhibit	50%	of	the	specific	binding.
where	[A]	 is	the	concentration	of	the	competing	 ligand	and	IC50 is 
the	concentration	at	which	half	of	the	specific	binding	of	[3H]prazo-
sin has been inhibited.
From the IC50	 value,	 the	known	concentration	of	 [3H]prazosin	
and	the	known	KD	for	[3H]prazosin	at	each	receptor,	a	KD	(concen-
tration at which half the receptors are bound by the competing li-
gand)	value	was	calculated	using	the	Cheng–Prusoff	equation:
In	 some	 cases,	 the	maximum	concentration	of	 competing	 ligand	
was not able to inhibit all of the specific binding. Where no inhibition 
of	[3H]prazosin	binding	was	seen,	even	with	maximum	concentration	
of	competing	ligand	possible,	“no	binding”	is	given	in	the	tables.	Where	
the	 inhibition	produced	by	 the	maximum	concentration	of	 the	com-
peting	 ligand	was	50%	or	 less,	an	 IC50 could not be determined and 





















4 of 16  |     PROUDMAN et Al.
greater	concentration	would	have	resulted	in	100%	inhibition.	These	
values	are	given	as	apparent	KD values in the tables.
For	some	ligands,	the	inhibition	of	[3H]prazosin	binding	was	best	
described	by	a	two-component	curve,	using	the	equation	below:
where	 [A]	 is	 the	concentration	of	 the	competing	 ligand,	 IC501 and 
IC502 are the respective IC50 values for the two components and N 
is the percentage of the response occurring through the first com-
ponent	(IC501).	KD values were calculated from IC50 values as above.
Selectivities	are	given	as	a	ratio	of	the	KD values for the different 
receptors.
3  | RESULTS
Saturation	 binding	 yielded	 a	 KD	 value	 for	 [3H]prazosin	 of	
0.71	 nmol/L	 ±	 0.07	 (1552	 ±	 166	 fmol/mg	 protein,	 n	 =	 11)	 at	 the	
human α1A-adrenoceptor,	0.87nM	±	0.11	(4350	±	317	fmol/mg	pro-
tein,	n	=	12)	at	the	human	α1B-adrenoceptor,	and	1.90	±	0.31	nmol/L	




peting	 prazosin	 with	 [3H]prazosin.	 The	 log	 KD values obtained 
were	−9.07	±	0.04	(=0.85	nmol/L,	n	=	9)	at	the	α1A-adrenoceptor,	
−8.74	 ±	 0.06	 (=1.82	 nmol/L,	 n	 =	 8)	 at	 the	α1B-adrenoceptor,	 and	







F I G U R E  1   Inhibition	of	[3H]prazosin	binding	to	whole	cells	by	doxazosin	(A–C),	SNAP5089	(D–F)	or	BMY7378	(G–I)	to	CHO-α1A	cells	(A,	
D,	G),	CHO-α1B	cells	(B,	E,	H),	or	CHO-α1D	cells	(C,	F,	I).	Bars	represent	total	[3H]prazosin	binding	and	nonspecific	binding	was	determined	
in the presence of 10 μmol/L	tamsulosin	(CHO-α1A	and	CHO-α1B)	or	100	μmol/L	tamsulosin	(CHO-α1D).	The	concentration	of	[3H]prazosin	
was	(A)	0.31	nmol/L,	(B)	0.31	nmol/L,	(C)	0.70	nmol/L,	(D)	0.68	nmol/L,	(E)	0.68	nmol/L,	(F)	0.60	nmol/L,	(G)	0.24	nmol/L,	(H)	0.42	nmol/L,	
and	(I)	1.25	nmol/L.	Data	points	are	mean	±	SE	mean	of	triplicate	determinations


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8 of 16  |     PROUDMAN et Al.
These values are all within twofold of the value obtained from sat-
uration studies. The values from saturation studies were used for 
further	KD	 calculations.	A	 lower	 receptor	 expression	 level	 for	 the	
full-length	α1D-adrenoceptors	is	a	common	finding15,33 and reports 
suggest	 truncation	 of	 the	 N-terminus	 results	 in	 higher	 receptor	
expressions.33-35
Doxazosin,	a	commonly	used	α blocker in the treatment of hy-
pertension,	 inhibited	 all	 three	 receptors	with	 high	 affinity	 (log	KD 
−8.58,	 −8.46,	 and	 −8.33	 at	 the	α1A,	 α1B,	 and	 α1D-adrenoceptor,	
respectively,	Figure	1,	Table	1).	Of	all	the	compounds	studied,	SNAP	
5089	 had	 the	 highest	 receptor	 selectivity,	 being	 over	 1700-fold	
selective for the α1A-adrenoceptor	 (Figure	 1,	 Table	 1).	 No	 com-
pound was found to have α1B-adrenoceptor	selectivity.	The	ability	
of	BMY7378	to	inhibit	[3H]prazosin	binding	was	best	described	by	
a	 two-component	 curve	with	 the	high-affinity	 component	 (log	KD 
−8.60	at	the	α1D-adrenoceptor)	giving	it	98-	and	234-fold	selectiv-
ity for the α1D-adrenoceptor	over	the	α1A	and	α1B-adrenoceptors,	
respectively	(Figure	1,	Table	1).	Several	compounds	had	affinities	of	
less	than	0.25nM,	 including	 ligands	with	α1A	selectivity	 (silodosin,	





2-chloroethylamines.	 Preincubation	 of	 phenoxybenzamine	 and	
dibenamine with sodium thiosulfate before addition to the cells 
yielded	 a	 single-component-binding	 inhibition	 (Figure	 2,	 Table	 2),	
whereby	 the	 high-affinity-binding	 component	 of	 the	 parent	 curve	
had been abolished. Sodium thiosulfate had no effect on the binding 
of	tamsulosin	(Figure	2,	Table	2).	At	the	α1D-adrenoceptor,	several	
F I G U R E  2   Inhibition	of	[3H]prazosin	binding	to	whole	cells	by	phenoxybenzamine	(A–C),	dibenamine	(D–F)	or	tamsulosin	(G–I)	to	CHO-
α1A	cells	(A,	D,	G),	CHO-α1B	cells	(B,	E,	H),	or	CHO-α1D	cells	(C,	F,	I).	Bars	represent	total	[3H]prazosin	binding	and	nonspecific	binding	was	
determined in the presence of 10 μmol/L	tamsulosin	(CHO-α1A	and	CHO-α1B)	or	100	μmol/L	tamsulosin	(CHO-α1D).	The	concentration	of	
[3H]prazosin	was	(A)	0.48	nmol/L,	(B)	0.48	nmol/L,	(C)	0.86	nmol/L,	(D)	0.58	nmol/L,	(E)	0.56	nmol/L,	(F)	1.49	nmol/L,	(G)	0.56	nmol/L,	(H)	
0.58	nmol/L,	and	(I)	1.49	nmol/L.	Data	points	are	mean	±	SE	mean	of	triplicate	determinations
     |  9 of 16PROUDMAN et Al.
TA B L E  2  Log	KD	values	of	phenoxybenzamine,	dibenamine	and	tamsulosin	binding	to	the	human	α1A,	α1B	and	α1D-adrenoceptors	
obtained	in	the	absence	and	presence	of	1	mmol/L	sodium	thiosulphate	(Figure	2).	Values	represent	mean	±	SE	mean	of	n	separate	
experiments
Control +1 mmol/L sodium thiosulphate
Log KD site 1 Log KD site 2 % site 1 n Log KD site 1 Log KD site 2 % site 1 n
CHO-α1A
Phenoxybenzamine −8.45	±	0.12 −6.02	±	0.08 77.7	±	5.2 12 −5.43	±	0.07 7
Dibenamine −7.91	±	0.06 −5.32	±	0.08 83.0	±	1.8 15 −5.16	±	0.10 7
Tamsulosin −9.67	±	0.06 17 −9.75	±	0.16 7
CHO-α1B
Phenoxybenzamine −7.69	±	0.06 −5.57	±	0.06 67.5	±	2.5 13 −5.18	±	0.05 6
Dibenamine −6.57	±	0.07 −4.66	±	0.06 67.6	±	2.6 14 −4.85	±	0.05 6
Tamsulosin −8.12	±	0.04 15 −8.13	±	0.08 6
CHO-α1D
Phenoxybenzamine −8.43	±	0.19 −5.42	±	0.08 39.1	±	2.0 10 −4.93	±	0.10 5
Dibenamine −7.37	±	0.15 −5.00	±	0.14 47.8	±	3.2 9 −4.74	±	0.09 5
Tamsulosin −9.18	±	0.08 −5.67	±	0.15 54.6	±	3.7 13 −9.11	±	0.12 −5.60	±	0.08 44.0	±	2.8 7
F I G U R E  3   Inhibition	of	[3H]prazosin	binding	to	whole	cells	by	two	commonly	prescribed	antidepressants	amtriptyline	(A–C)	or	trazodone	
(D–F)	to	CHO-α1A	cells	(A,	D),	CHO-α1B	cells	(B,	E),	or	CHO-α1D	cells	(C,	F).	Bars	represent	total	[3H]prazosin	binding	and	nonspecific	
binding was determined in the presence of 10 μmol/L	tamsulosin	(CHO-α1A	and	CHO-α1B)	or	100	μmol/L	tamsulosin	(CHO-α1D).	The	
concentration	of	[3H]prazosin	was	a)	0.39	nmol/L,	(B)	0.45	nmol/L,	(C)	0.57	nmol/L,	(D)	0.66	nmol/L,	(E)	0.45	nmol/L,	and	(F)	0.66	nmol/L.	
Data	points	are	mean	±	SE	mean	of	triplicate	determinations
10 of 16  |     PROUDMAN et Al.
other	ligands	were	best	described	by	a	two-component-binding	in-
hibition	curve.	Just	as	with	tamsulosin	(Figure	2),	preincubation	with	
sodium thiosulfate had no effect on either component of any of 
these	other	two-component	ligands.
The affinity of several antidepressants and antipsychot-
ics	 was	 then	 examined.	 Several	 of	 these	 were	 found	 to	 have	
high α1-adrenoceptor	 affinity	 (Figures	 3	 and	4,	 Table	 3	 and	4).	
Risperidone	 (previously	 suggested	 to	 have	 α1B	 selectivity,4,36 
had slight α1A	 selectivity,	 in	 keeping	 with	 the	 findings	 of37. 
There	 have	 also	 been	 discrepancies	 in	 the	 affinity	 of	 olanzap-
ine: Richelson and Souder27	found	it	to	have	high	affinity	(44nM	
for α1-adrenoceptor)	 and	 Nourain	 et	 al,29 had conflicting data 
with low rat α1-adreoceptor	affinity,	but	significant	hypotension	
in	 rats.	 However,	 here,	 olanzepine	 had	 low	 affinity,	 in	 keeping	
with38 and the findings of39	where	olanzapine	was	described	as	
having	 low	 postural	 hypotension	 potential.	 WB4104,	 was	 also	
initially thought to have α1B	selectivity,40	however,	it	had	higher	
and	 equal	 affinity	 for	 α1A	 and	 α1D-adrenoceptors	 (in	 keeping	
with41,42).
Tables combing all of these ligands are presented in 




Dibenamine,	 phentolamine,	 and	phenoxybenzamine	were	 the	 first	
clinical α blockers43	 and	 phenoxybenzamine	 is	 still	 used	 in	 the	
management	 of	 pheochromocytoma,	 particularly	 during	 surgery	
where catastrophic catecholamine release can cause hypertensive 
crises and arrhythmias.7	Both	phenoxybenzamine	 and	dibenamine	
are N,N-disubstituted-2-chloroethylamines	 containing	 a	 nitrogen	
mustard	 group.	 Both	 compounds	 were	 best	 described	 by	 a	 two-
component-binding	 inhibition	 curve	 at	 all	 three	 α1-adrenoceptors	
(Figure	2,	Table	1).	 In	aqueous	solution	at	physiological	pH,	the	ni-
trogen	mustard	group	cyclizes	to	form	ethyleniminium	ions.44 These 
highly	 reactive,	 unstable	 ions	 are	 pharmacologically	 active	 and	
covalently bind to a cysteine in transmembrane 3 of the α adreno-
ceptors,	 giving	 these	 compounds	 their	 “irreversible”	 properties.43 
Phenoxybenzamine	has	a	longer	duration	of	action	in	clinical	studies	
than phentolamine 7 and hence its continued use in pheochromo-
cytoma	(although	similar	outcomes	have	been	reported	with	doxa-
zosin,	 terazosin,	 and	prazosin,.45-47 Sodium thiosulfate also rapidly 
reacts with the ethyleniminium ions thus prevents them from inter-
acting with α adrenoceptors.44	 Pretreatment	with	 intravenous	 so-
dium thiosulfate prevented dibenamine binding to α adrenoceptors 
(in	cats,48 and pretreatment with sodium thiosulfate prevented the 
F I G U R E  4   Inhibition	of	[3H]prazosin	
binding to whole cells by two commonly 













mean of triplicate determinations
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nent suggests that it was due to specific α1-adrenoceptor	 interac-
tion.	The	KD	values	of	the	low-affinity	components	were	very	similar	





tor,	including	tamsulosin	(and	hence	why	100	μM was used to define 
nonspecific	 binding	 in	CHO-α1D	 cells,	 rather	 than	 10	μM used in 
α1A	and	α1B	cells),	and	the	only	α1D-selective	ligand,	BMY7378.	As	
expected	for	these	nonmustard	compounds,	preincubation	with	so-
dium thiosulfate had no effect on binding. The reason for the second 
component	 is	 therefore	unknown.	Affinity	 (KD	 value)	obtained	 for	
the	high-affinity	component	 the	α1D-adrenoceptor	has	been	used	
to determine receptor selectivity.











be	 expected	 that	 drugs	 like	 tamsulosin	 and	 alfuzosin,	 licensed	 for	
BPH,	are	 likely	 to	have	as	much	of	an	effect	on	blood	pressure	as	
α blockers intentionally prescribed for hypertension. Several other 









Labetolol	has	 lower	affinity	 than	carvedilol	 for	all	β52 and α1-ad-
renoceptors	 (log	KD	−7.33	at	α1A),	but	very	poor	affinity	 for	 the	
α1B	 and	 α1D-adrenoceptors.	 Labetolol	 should	 be	 considered	 a	
β1/β2/α1A	blocker	 rather	 than	dual	 pan	α1 and β blocker. Given 
these dual α/β	 ligands,	 the	affinity	of	a	 few	β blockers with very 








tors. Other α1A-selective	 ligands	were	silodosin,	RS100329,	and	
niguldipine	 (in	 keeping	 with50,54).	 As	 well	 as	 tamsulosin,	 several	
ligands had higher affinity for the α1A	 and	 α1D receptors than 
the α1B—for	 example,	 2-MPMDQ,	MK-912,	 2-PMDQ,	 and	 ifen-
prodil.	 BMY7378	 was	 the	 only	 compound	 with	 substantial	 α1D 
selectivity	(the	100-	to	200-fold	selectivity	is	similar	to6,20,41,50,55).	
No α1B-selective	ligand	was	identified.	To	pharmacologically	infer	
the presence of α1B-adrenoceptors	in	cells	or	tissues,	several	dif-




for the α1-adrenoceptors.	 Amitriptyline,	 clomipramine,	 doxepin,	
and nortriptyline have similar α1-adrenoceptor	 affinities	 and	 se-
lectivities to α	blockers	prescribed	for	hypertension	or	BPH.	Thus	
patients	taking	these	TCAs	should	be	considered	to	be	α blocked 
and	are	 at	 risk	 from	postural	 hypotension	 (as	 in23).	 Furthermore,	
the addition of an α	blocker	for	concomitant	hypertension	or	BPH	
may not have any additional clinical benefit and may actually cause 
significant	 postural	 problems.	 Other	 TCA	 had	 lower	 affinity,	 for	
example,	 protriptyline	 and	 lofepramine	 and	 would	 therefore	 be	
expected	to	have	less	effect	on	blood	pressure.	The	selective	se-
rotonin	reuptake	inhibitors	(SSRIs)	had	very	poor	affinity	for	any	of	
the α adrenoceptors and are therefore less likely to have significant 
α1-mediated	hypotension.
Several	 antipsychotics	 (including	 first-generation	 chlorprom-
azine	 and	 flupenthixol	 and	 second-generation	 sertindole,	 risperi-
done,	 and	 clozapine)	 had	 high	 α1-adrenoceptor	 affinity.	 The	 very	
high	 affinity	 of	 sertindole	 (and	 300-fold	 selectivity	 for	 α1A	 over	
α1D-adrenoceptors)	was	similar	to	previous	reports.6,29 The degree 
of α1A-adrenoceptor	affinity	observed	here	correlates	well	with	the	
rankings for observations in rats.29 The high α1A	affinity	of	sertin-
dole,	risperidone,	and	ziprasidone	(log	KD	−9.3	to	−8.7)	is	similar	to	
studies,38	 including	 in	brain	tissue,27	and	similar	to	 (or	even	higher	
than)	that	for	many	drugs	used	to	treat	hypertension.	The	high	rate	
of postural hypotension observed with these drugs31,32 is therefore 
not	surprising.	A	similar	hypotensive	effect	would	be	expected	with	
other antipsychotics α1	affinities	equal	or	greater	than	that	for	α1 
blockers	 used	 for	 hypertension,	 for	 example,	 chlorpromazine,	 flu-
penthixol,	 perphenazine,	 paliperidone,	 quetiapine,	 and	 lurasidone.	
Aripiprazole	had	lower	α1	affinity	(in	keeping	with56 and indeed has 
a relative lack of reported postural hypotension in clinical studies57).	
However,	sulpiride	and	amisulpiride	would	be	expected	to	have	even	
less hypotensive effect.
Thus,	the	high	α1 affinity and selectivity profile of many antipsy-
chotics is comparable to the α1 blockers intentionally prescribed for 
hypertension.	 Equivalent	 reductions	 in	 blood	 pressure	 are	 a	 likely	
very	common	side	effect.	These	drugs	are	used	to	manage	schizo-
phrenia where their effect on blood pressure in agitated patients is 
less	 likely	 to	be	 an	 issue.	However,	 antipsychotics	 are	 also	widely	
used to manage delirium in sick patients including the intensive care 
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unit58,59 and in palliative case60,61 even though recent studies have 
questioned	 their	 effectiveness.62 Delirium is common in older un-
well patients who are more likely to be suffering from conditions 
with	lower	blood	pressure	such	as	sepsis.	In	these	cases,	the	choice	
of	antipsychotic	may	well	be	 important	 in	order	not	to	exacerbate	
already low or labile blood pressures. This study suggests that sulpir-
ide,	amisulpiride,	ariprazole,	and	olazepine	should	have	the	least	ef-
fect on blood pressure.
In	 conclusion,	 there	 are	 several	 highly	 α1A-selective	 an-
tagonists	 (eg,	 SNAP5089),	 and	 one	 α1D-selective	 antagonist	
(BMY7378),	however	no	α1B-selective	ligand	has	been	identified.	
The	 drugs	 used	 for	 hypertension	 and	 BPH	 have	 a	 very	 similar	
pharmacological profile in terms of α1-adrenoceptor	subtype	af-
finity and selectivity. Several antidepressants and antipsychotics 
have high α1-adrenoceptor	 affinities,	 similar	 to,	 or	 even	greater	
than,	those	seen	for	α blockers prescribed for hypertension and 
BPH.	The	addition	of	 further	α blockers for the management of 
hypertension	 or	 BPH	 in	 these	 patients	 may	 not	 be	 beneficial.	
The	excellent	correlation	between	the	affinity	values	determined	
from this cell studies with the affinities measured in blood ves-
sels,	 brain	 tissue,	 and	 whole	 animals	 (including	 humans)	 means	
that	 many,	 but	 not	 all	 antipsychotics	 and	 antidepressant	 may	
cause significant peripheral α-adrenoceptor	blockade	and	associ-
ated	hypotension.	Finally,	awareness	of	the	α-blocking	potential	
of	certain,	but	not	all	antipsychotics	may	affect	the	choice	of	drug	
used for the management of delirium in the intensive care unit 
where additional α blockade and blood pressure lowering in a sick 
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